





Intas Group	4
Intas 3P Global Set Up	5
Our History	6
R & D	7
Manufacturing Capabilities	8
Quality	10
Clinical Research & Pharmacovigilance	10
Future novel technology development	11





Intas 3P Global Set Up

Intas Group

- Leading Global Pharmaceutical company.
- Headquartered in Ahmedabad, India.
- Vertically integrated: API → Formulation → Development → Manufacturing → Licensing → Supply.
- 10 manufacturing sites, in India, Mexico and UK.
- Global strategy including alliances with wide platform of pharma companies.
- Global sales of USD 700 million.
- 50% sales to regulated international markets.



Ahmedabad, India
R&D and Manufacturing.

London, UK
Regulatory, EU Testing and Release labs., Primary & Secondary Packaging and Warehousing.

Barcelona, Spain
Worldwide Management, BD&L for EMEA, IP, A/W, Compliance Management, Supply Chain, Legal and EU Testing & Release labs.

Melbourne, Australia
BD&L for APAC.

Montreal, Canada
BD&L for Canada.

São Paulo, Brazil
BD&L for LATAM.

MELBOURNE

1976

Founded by *Shri Hasmukh K. Chudgar.*

1996

Matoda GMP facility completed.

1999

Clinical Research affiliate foundation.

2000

Biotech affiliate foundation.

2001

Contract Research affiliate foundation.

2003

Cytotoxic facility commissioned at Matoda.

2006

FDA approval of Matoda manufacturing site.

2007

New cytotoxic API plant commissioned.

2010

Start production at new manufacturing site - SEZ.

2011

Entered Top 10 ranking in India.

2013

First Indian origin biosimilar approved in EU (G-CSF).

2014

Global first Nanosomal Docetaxel launch.
New EU testing & release facilities in Barcelona, Spain.

01 Our History

02 R&D



Intas R&D team provides development services to pharma companies across the world.

Over 400 research scientists for non-clinical product research.

New EU testing & release facilities in Barcelona to provide complete QP services for EU markets.

03 Manufacturing Capabilities

Matoda site in operation since 1996.

SEZ site in operation since 2010.

Own production of APIs (high potency & standard APIs).

Pharmaceutical form	Capacity / year
Solid orals	
Tablets	10,200 million
Capsules	940 million
Effervescent tablets	300 million
Pellets	30,000 kg
Anti-cancer	
Tablets and capsules	600 million
Liquid vials	15 million
Lyo vials	4.3 million
PFS	1.5 million
Ointments	24,000 Kg
Standard IV products	
Liquid vials	30 million
Lyo vials	3 million
Liquid ampoules	85 million
PFS	7 million

Matoda. Manufacturing & API Site. Ahmedabad, Gujarat, India.



SEZ. Manufacturing Site. Ahmedabad, Gujarat, India.



04 Quality

Full cGMP approvals from prominent international regulatory bodies:



US (FDA), Europe (EMA), Australia (TGA), UK (MHRA), Brazil (ANVISA), South Africa (MCC), Turkey (T.C. Sağlık Bakanlığı) and Gulf (GCC), ANMAT (Argentina)

Environmental concerned company:

- ISO 14001:2004 Hazard Identification.
- OHSAS 18001:2007 Risk Assessment and Control.



05 Clinical Research & PV

Intas' Clinical Research Organization (CRO) is one of the biggest in India.

Centers in North America and Europe -> Global clinical research across 3 continents.

550 clinical research employees.

Performed about 5,000 clinical trials: Phase I – IV and BE studies.

More than 500 submissions in North America, Europe and Australia.

Pharmacovigilance services to meet EU PV obligations.

06

Future novel technology development

Biosimilars

Intas' biotech affiliate is front-runner in the Indian biopharmaceutical sector. **First Indian origin biosimilar approved in EU (G-CSF).**

Fully integrated R&D and manufacturing capabilities. Microbial & mammalian cell platforms.

cGMP approved by EU authorities and full R&D services.

Launched in India:

- G-CSF
- Peg-G-CSF
- Interferon α -2b
- Peg-Interferon α -2b
- EPO- α
- Rituximab
- PTH
- FSH

Pipeline of 12 new biosimilars including mAbs.

New Drug Delivery Systems

Cutting edge nanosomal technology.

Global first Nanosomal Docetaxel approved by Indian Regulatory Agency.

Lipid platform to be applied to other molecules.

Growth lies with the choice of partners...

Dossiers approved worldwide in EU, USA, Canada, Australia, Latin America, etc.

Strong focus on oncology and CNS areas.

Product portfolio of 100+ products.

Platform of customers on a global basis.

Intas is one of the largest Indian pharmaceutical organizations with presence across the globe.



Intas Pharmaceuticals Ltd.

Head Office

Chinubhai Centre, Ashram Road,
Ahmedabad - 380009, Gujarat - India
Phone: +91 79 265 766 55 - **Fax:** +91 79 265 788 62

www.intaspharma.com

Global Licensing & Third Party Sales Office

World Trade Center, Edifici Est, 6 planta
Moll de Barcelona s/n, 08039 Barcelona - Spain
Phone: +34 93 301 73 51 - **Fax:** +34 93 318 38 03

intas3P@intaspharma.com